Multiple roles for orexin/hypocretin in addiction

Progress in Brain Research

Volumn 198, Issue , 2012, Pages 79-121

  Mahler, Stephen V ^a   Smith, Rachel J ^a   Moorman, David E ^a   Sartor, Gregory C ^a   Aston Jones, Gary ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Cocaine; Cues; Ethanol; Food; Glutamate; Motivation; Nicotine; Opiates

Indexed keywords

1 (2 METHYL 6 BENZOXAZOLYL) 3 (1,5 NAPHTHYRIDIN 4 YL)UREA; ALCOHOL; AMPHETAMINE; COCAINE; GLUTAMIC ACID; NICOTINE; OPIATE; OREXIN; OREXIN 1 RECEPTOR; OREXIN 2 RECEPTOR; OREXIN A; OREXIN B;

ADDICTION; ARTICLE; BRAIN VENTRICLE; DRUG DEPENDENCE; DRUG SEEKING BEHAVIOR; DRUG SELF ADMINISTRATION; DRUG SENSITIZATION; DRUG WITHDRAWAL; NONHUMAN; NUCLEUS ACCUMBENS; PLACE PREFERENCE; PRIORITY JOURNAL;

EID: 84863866948     PISSN: 00796123     EISSN: 18757855     Source Type: Book Series    
DOI: 10.1016/B978-0-444-59489-1.00007-0     Document Type: Chapter

References (332)

1. Adamantidis A., de Lecea L. The hypocretins as sensors for metabolism and arousal. The Journal of Physiology 2009, 587:33-40.
2. Adamantidis A.R., Zhang F., Aravanis A.M., Deisseroth K., de Lecea L. Neural substrates of awakening probed with optogenetic control of hypocretin neurons. Nature 2007, 450:420-424.
3. Akanmu M.A., Honda K. Selective stimulation of orexin receptor type 2 promotes wakefulness in freely behaving rats. Brain Research 2005, 1048:138-145.
4. Diagnostic and statistical manual of mental disorders: DSM-IV-TR 2000, APA, American Psychiatric Association, Washington, DC.
5. Aston-Jones G., Harris G.C. Brain substrates for increased drug seeking during protracted withdrawal. Neuropharmacology 2004, 47(Suppl. 1):167-179.
6. Aston-Jones G., Smith R.J., Sartor G.C., Moorman D.E., Massi L., Tahsili-Fahadan P., et al. Lateral hypothalamic orexin/hypocretin neurons: A role in reward-seeking and addiction. Brain Research 2010, 1314:74-90.
7. Azizi H., Mirnajafi-Zadeh J., Rohampour K., Semnanian S. Antagonism of orexin type 1 receptors in the locus coeruleus attenuates signs of naloxone-precipitated morphine withdrawal in rats. Neuroscience Letters 2010, 482:255-259.
8. Badiani A., Belin D., Epstein D., Calu D., Shaham Y. Opiate versus psychostimulant addiction: The differences do matter. Nature Reviews. Neuroscience 2011, 12:685-700.
9. Baimel C., Borgland S.L. Hypocretinmodulation of drug-induced synaptic plasticity. Progress in Brain Research 2012, 198.
10. Balcita-Pedicino J.J., Sesack S.R. Orexin axons in the rat ventral tegmental area synapse infrequently onto dopamine and gamma-aminobutyric acid neurons. The Journal of Comparative Neurology 2007, 503:668-684.
11. Baldo B.A., Daniel R.A., Berridge C.W., Kelley A.E. Overlapping distributions of orexin/hypocretin- and dopamine-beta-hydroxylase immunoreactive fibers in rat brain regions mediating arousal, motivation, and stress. The Journal of Comparative Neurology 2003, 464:220-237.
12. Baldo B.A., Gual-Bonilla L., Sijapati K., Daniel R.A., Landry C.F., Kelley A.E. Activation of a subpopulation of orexin/hypocretin-containing hypothalamic neurons by GABAA receptor-mediated inhibition of the nucleus accumbens shell, but not by exposure to a novel environment. The European Journal of Neuroscience 2004, 19:376-386.
13. Baldo B.A., Kelley A.E. Discrete neurochemical coding of distinguishable motivational processes: Insights from nucleus accumbens control of feeding. Psychopharmacology 2007, 191:439-459.
14. Balleine B.W., O'Doherty J.P. Human and rodent homologies in action control: Corticostriatal determinants of goal-directed and habitual action. Neuropsychopharmacology 2010, 35:48-69.
15. Bardo M.T., Bevins R.A. Conditioned place preference: What does it add to our preclinical understanding of drug reward?. Psychopharmacology 2000, 153:31-43.
16. Bayer L., Eggermann E., Serafin M., Grivel J., Machard D., Muhlethaler M., et al. Opposite effects of noradrenaline and acetylcholine upon hypocretin/orexin versus melanin concentrating hormone neurons in rat hypothalamic slices. Neuroscience 2005, 130:807-811.
17. Bayerlein K., Kraus T., Leinonen I., Pilniok D., Rotter A., Hofner B., et al. Orexin A expression and promoter methylation in patients with alcohol dependence comparing acute and protracted withdrawal. Alcohol 2011, 45:541-547.
18. Belin D., Mar A.C., Dalley J.W., Robbins T.W., Everitt B.J. High impulsivity predicts the switch to compulsive cocaine-taking. Science 2008, 320:1352-1355.
19. Berke J.D., Hyman S.E. Addiction, dopamine, and the molecular mechanisms of memory. Neuron 2000, 25:515-532.
20. Bernstein J.G., Boyden E.S. Optogenetic tools for analyzing the neural circuits of behavior. Trends in Cognitive Science 2011, 15:592-600.
21. Berridge K.C. The debate over dopamine's role in reward: The case for incentive salience. Psychopharmacology 2007, 191:391-431.
22. Berridge C.W., Espana R.A., Vittoz N.M. Hypocretin/orexin in arousal and stress. Brain Research 2010, 1314:91-102.
23. Berridge K.C., Ho C.Y., Richard J.M., DiFeliceantonio A.G. The tempted brain eats: Pleasure and desire circuits in obesity and eating disorders. Brain Research 2010, 1350:43-64.
24. Berridge K.C., Robinson T.E. What is the role of dopamine in reward: Hedonic impact, reward learning, or incentive salience?. Brain Research. Brain Research Reviews 1998, 28:309-369.
25. Berridge K.C., Robinson T.E. Parsing reward. Trends in Neurosciences 2003, 26:507-513.
26. Berthoud H.R. Metabolic and hedonic drives in the neural control of appetite: Who is the boss?. Current Opinion in Neurobiology 2011, 21:888-896.
27. Bickel W.K., Yi R., Mueller E.T., Jones B.A., Christensen D.R. The behavioral economics of drug dependence: Towards the consilience of economics and behavioral neuroscience. Current Topics in Behavioral Neurosciences 2010, 3:319-341.
28. Borgland S.L., Chang S.J., Bowers M.S., Thompson J.L., Vittoz N., Floresco S.B., et al. Orexin A/hypocretin-1 selectively promotes motivation for positive reinforcers. The Journal of Neuroscience 2009, 29:11215-11225.
29. Borgland S.L., Storm E., Bonci A. Orexin B/hypocretin 2 increases glutamatergic transmission to ventral tegmental area neurons. The European Journal of Neuroscience 2008, 28:1545-1556.
30. Borgland S.L., Taha S.A., Sarti F., Fields H.L., Bonci A. Orexin A in the VTA is critical for the induction of synaptic plasticity and behavioral sensitization to cocaine. Neuron 2006, 49:589-601.
31. Bouton M.E., Bolles R.C. Role of conditioned contextual stimuli in reinstatement of extinguished fear. Journal of Experimental Psychology. Animal Behavior Processes 1979, 5:368-378.
32. Boutrel B., de Lecea L. Addiction and arousal: The hypocretin connection. Physiology and Behavior 2008, 93:947-951.
33. Boutrel B., Kenny P.J., Specio S.E., Martin-Fardon R., Markou A., Koob G.F., et al. Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking behavior. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:19168-19173.
34. Brandon T.H., Vidrine J.I., Litvin E.B. Relapse and relapse prevention. Annual Review of Clinical Psychology 2007, 3:257-284.
35. Breiter H.C., Gollub R.L., Weisskoff R.M., Kennedy D.N., Makris N., Berke J.D., et al. Acute effects of cocaine on human brain activity and emotion. Neuron 1997, 19:591-611.
36. Brisbare-Roch C., Dingemanse J., Koberstein R., Hoever P., Aissaoui H., Flores S., et al. Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nature Medicine 2007, 13:150-155.
37. Bromberg-Martin E.S., Matsumoto M., Hikosaka O. Dopamine in motivational control: Rewarding, aversive, and alerting. Neuron 2010, 68:815-834.
38. Brown E.E., Robertson G.S., Fibiger H.C. Evidence for conditional neuronal activation following exposure to a cocaine-paired environment: Role of forebrain limbic structures. The Journal of Neuroscience 1992, 12:4112-4121.
39. Brown Z.J., Tribe E., D'Souza N.A., Erb S. Interaction between noradrenaline and corticotrophin-releasing factor in the reinstatement of cocaine seeking in the rat. Psychopharmacology 2009, 203:121-130.
40. Buffalari D.M., See R.E. Inactivation of the bed nucleus of the stria terminalis in an animal model of relapse: Effects on conditioned cue-induced reinstatement and its enhancement by yohimbine. Psychopharmacology 2011, 213:19-27.
41. Cabanac M. Physiological role of pleasure. Science 1971, 173:1103-1107.
42. Cai X.J., Widdowson P.S., Harrold J., Wilson S., Buckingham R.E., Arch J.R., et al. Hypothalamic orexin expression: Modulation by blood glucose and feeding. Diabetes 1999, 48:2132-2137.
43. Cami J., Farre M. Drug addiction. The New England Journal of Medicine 2003, 349:975-986.
44. Cannella N., Economidou D., Kallupi M., Stopponi S., Heilig M., Massi M., et al. Persistent increase of alcohol-seeking evoked by neuropeptide S: An effect mediated by the hypothalamic hypocretin system. Neuropsychopharmacology 2009, 34:2125-2134.
45. Carr D.B., Sesack S.R. Projections from the rat prefrontal cortex to the ventral tegmental area: Target specificity in the synaptic associations with mesoaccumbens and mesocortical neurons. The Journal of Neuroscience 2000, 20:3864-3873.
46. Carter M.E., Adamantidis A., Ohtsu H., Deisseroth K., de Lecea L. Sleep homeostasis modulates hypocretin-mediated sleep-to-wake transitions. The Journal of Neuroscience 2009, 29:10939-10949.
47. Cason, A., & Aston-Jones, G. (submitted). Role of orexin / hypocretin in conditioned sucrose-seeking.
48. Cason A.M., Smith R.J., Tahsili-Fahadan P., Moorman D.E., Sartor G.C., Aston-Jones G. Role of orexin/hypocretin in reward-seeking and addiction: Implications for obesity. Physiology and Behavior 2010, 100:419-428.
49. Tobacco-related mortality 2011, CDCP, Centers for Disease Control and Prevention.
50. Cheer J.F., Aragona B.J., Heien M.L., Seipel A.T., Carelli R.M., Wightman R.M. Coordinated accumbal dopamine release and neural activity drive goal-directed behavior. Neuron 2007, 54:237-244.
51. Chester J.A., Cunningham C.L. Baclofen alters ethanol-stimulated activity but not conditioned place preference or taste aversion in mice. Pharmacology, Biochemistry, and Behavior 1999, 63:325-331.
52. Childs E., de Wit H. Amphetamine-induced place preference in humans. Biological Psychiatry 2009, 65:900-904.
53. Choi D.L., Davis J.F., Fitzgerald M.E., Benoit S.C. The role of orexin-A in food motivation, reward-based feeding behavior and food-induced neuronal activation in rats. Neuroscience 2010, 167:11-20.
54. Ciccocioppo R., Sanna P.P., Weiss F. Cocaine-predictive stimulus induces drug-seeking behavior and neural activation in limbic brain regions after multiple months of abstinence: Reversal by D(1) antagonists. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:1976-1981.
55. Clarke P.B.S., Kumar R. The effects of nicotine on locomotor activity in nontolerant and tolerant rats. British Journal of Pharmacology 1983, 78:329-337.
56. Clegg D.J., Air E.L., Woods S.C., Seeley R.J. Eating elicited by orexin-a, but not melanin-concentrating hormone, is opioid mediated. Endocrinology 2002, 143:2995-3000.
57. Cluderay J.E., Harrison D.C., Hervieu G.J. Protein distribution of the orexin-2 receptor in the rat central nervous system. Regulatory Peptides 2002, 104:131-144.
58. Coleman P.J., Schreier J.D., Roecker A.J., Mercer S.P., McGaughey G.B., Cox C.D., et al. Discovery of 3,9-diazabicyclo[4.2.1]nonanes as potent dual orexin receptor antagonists with sleep-promoting activity in the rat. Bioorganic & Medicinal Chemistry Letters 2010, 20:4201-4205.
59. Crombag H.S., Bossert J.M., Koya E., Shaham Y. Review. Context-induced relapse to drug seeking: A review. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences 2008, 363:3233-3243.
60. Date Y., Ueta Y., Yamashita H., Yamaguchi H., Matsukura S., Kangawa K., et al. Orexins, orexigenic hypothalamic peptides, interact with autonomic, neuroendocrine and neuroregulatory systems. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:748-753.
61. Dayas C.V., McGranahan T.M., Martin-Fardon R., Weiss F. Stimuli linked to ethanol availability activate hypothalamic CART and orexin neurons in a reinstatement model of relapse. Biological Psychiatry 2008, 63:152-157.
62. de Lecea L. Hypocretins and the neurobiology of sleep-wake mechanisms. Progress in Brain Research 2012, 198.
63. de Lecea L., Kilduff T.S., Peyron C., Gao X., Foye P.E., Danielson P.E., et al. The hypocretins: Hypothalamus-specific peptides with neuroexcitatory activity. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:322-327.
64. de Wit H., Stewart J. Reinstatement of cocaine-reinforced responding in the rat. Psychopharmacology 1981, 75:134-143.
65. de Wit H., Stewart J. Drug reinstatement of heroin-reinforced responding in the rat. Psychopharmacology 1983, 79:29-31.
66. Deadwyler S.A., Porrino L., Siegel J.M., Hampson R.E. Systemic and nasal delivery of orexin-A (Hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates. The Journal of Neuroscience 2007, 27:14239-14247.
67. Deroche-Gamonet V., Belin D., Piazza P.V. Evidence for addiction-like behavior in the rat. Science 2004, 305:1014-1017.
68. Dhaher R., Hauser S.R., Getachew B., Bell R.L., McBride W.J., McKinzie D.L., et al. The orexin-1 receptor antagonist SB-334867 reduces alcohol relapse drinking, but not alcohol-seeking, in alcohol-preferring (P) rats. Journal of Addiction Medicine 2010, 4:153-159.
69. Dhuria S.V., Hanson L.R., Frey W.H. Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system. Journal of Pharmaceutical Sciences 2009, 98:2501-2515.
70. Di Ciano P. Facilitated acquisition but not persistence of responding for a cocaine-paired conditioned reinforcer following sensitization with cocaine. Neuropsychopharmacology 2008, 33:1426-1431.
71. Di Ciano P., Everitt B.J. Neuropsychopharmacology of drug seeking: Insights from studies with second-order schedules of drug reinforcement. European Journal of Pharmacology 2005, 526:186-198.
72. Di Fabio R., Pellacani A., Faedo S., Roth A., Piccoli L., Gerrard P., et al. Discovery process and pharmacological characterization of a novel dual orexin 1 and orexin 2 receptor antagonist useful for treatment of sleep disorders. Bioorganic & Medicinal Chemistry Letters 2011, 21:5562-5567.
73. Di Sebastiano A.R., Wilson-Perez H.E., Lehman M.N., Coolen L.M. Lesions of orexin neurons block conditioned place preference for sexual behavior in male rats. Hormones and Behavior 2011, 59:1-8.
74. Di Sebastiano A.R., Yong-Yow S., Wagner L., Lehman M.N., Coolen L.M. Orexin mediates initiation of sexual behavior in sexually naive male rats, but is not critical for sexual performance. Hormones and Behavior 2010, 58:397-404.
75. Downs A.W., Eddy N.B. The effect of repeated doses of cocaine on the rat. The Journal of Pharmacology and Experimental Therapeutics 1932, 46:199-202.
76. Dugovic C., Shelton J.E., Aluisio L.E., Fraser I.C., Jiang X., Sutton S.W., et al. Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat. The Journal of Pharmacology and Experimental Therapeutics 2009, 330:142-151.
77. Dumont E.C., Mark G.P., Mader S., Williams J.T. Self-administration enhances excitatory synaptic transmission in the bed nucleus of the stria terminalis. Nature Neuroscience 2005, 8:413-414.
78. Dzung Le A., Funk D., Harding S., Juzytsch W., Fletcher P.J. The role of noradrenaline and 5-hydroxytryptamine in yohimbine-induced increases in alcohol-seeking in rats. Psychopharmacology 2009, 204:477-488.
79. Ellis J., Pediani J.D., Canals M., Milasta S., Milligan G. Orexin-1 receptor-cannabinoid CB1 receptor heterodimerization results in both ligand-dependent and -independent coordinated alterations of receptor localization and function. The Journal of Biological Chemistry 2006, 281:38812-38824.
80. Espana R.A., Melchior J.R., Roberts D.C., Jones S.R. Hypocretin 1/orexin A in the ventral tegmental area enhances dopamine responses to cocaine and promotes cocaine self-administration. Psychopharmacology 2011, 214:415-426.
81. Espana R.A., Oleson E.B., Locke J.L., Brookshire B.R., Roberts D.C., Jones S.R. The hypocretin-orexin system regulates cocaine self-administration via actions on the mesolimbic dopamine system. The European Journal of Neuroscience 2010, 31:336-348.
82. Estabrooke I.V., McCarthy M.T., Ko E., Chou T.C., Chemelli R.M., Yanagisawa M., et al. Fos expression in orexin neurons varies with behavioral state. The Journal of Neuroscience 2001, 21:1656-1662.
83. Everitt B.J., Belin D., Economidou D., Pelloux Y., Dalley J.W., Robbins T.W. Review. Neural mechanisms underlying the vulnerability to develop compulsive drug-seeking habits and addiction. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences 2008, 363:3125-3135.
84. Fadel J., Deutch A.Y. Anatomical substrates of orexin-dopamine interactions: Lateral hypothalamic projections to the ventral tegmental area. Neuroscience 2002, 111:379-387.
85. Feltenstein M.W., See R.E. The neurocircuitry of addiction: An overview. British Journal of Pharmacology 2008, 154:261-274.
86. Fenno L., Yizhar O., Deisseroth K. The development and application of optogenetics. Annual Review of Neuroscience 2011, 34:389-412.
87. Ferguson S.G., Shiffman S. The relevance and treatment of cue-induced cravings in tobacco dependence. Journal of Substance Abuse Treatment 2009, 36:235-243.
88. Fiorillo C.D., Tobler P.N., Schultz W. Discrete coding of reward probability and uncertainty by dopamine neurons. Science 2003, 299:1898-1902.
89. Franklin T.R., Druhan J.P. Expression of Fos-related antigens in the nucleus accumbens and associated regions following exposure to a cocaine-paired environment. The European Journal of Neuroscience 2000, 12:2097-2106.
90. Frederick-Duus D., Guyton M.F., Fadel J. Food-elicited increases in cortical acetylcholine release require orexin transmission. Neuroscience 2007, 149:499-507.
91. Fronczek R., Lammers G.J., Balesar R., Unmehopa U.A., Swaab D.F. The number of hypothalamic hypocretin (orexin) neurons is not affected in Prader-Willi syndrome. The Journal of Clinical Endocrinology and Metabolism 2005, 90:5466-5470.
92. Fu L.Y., Acuna-Goycolea C., van den Pol A.N. Neuropeptide Y inhibits hypocretin/orexin neurons by multiple presynaptic and postsynaptic mechanisms: Tonic depression of the hypothalamic arousal system. The Journal of Neuroscience 2004, 24:8741-8751.
93. Fuchs R.A., Branham R.K., See R.E. Different neural substrates mediate cocaine seeking after abstinence versus extinction training: A critical role for the dorsolateral caudate-putamen. The Journal of Neuroscience 2006, 26:3584-3588.
94. Fujiki N., Yoshida Y., Ripley B., Mignot E., Nishino S. Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog. Sleep 2003, 26:953-959.
95. Geisler S., Derst C., Veh R.W., Zahm D.S. Glutamatergic afferents of the ventral tegmental area in the rat. The Journal of Neuroscience 2007, 27:5730-5743.
96. Georges F., Aston-Jones G. Potent regulation of midbrain dopamine neurons by the bed nucleus of the stria terminalis. The Journal of Neuroscience 2001, 21:RC160.
97. Georges F., Aston-Jones G. Activation of ventral tegmental area cells by the bed nucleus of the stria terminalis: A novel excitatory amino acid input to midbrain dopamine neurons. The Journal of Neuroscience 2002, 22:5173-5187.
98. Georgescu D., Zachariou V., Barrot M., Mieda M., Willie J.T., Eisch A.J., et al. Involvement of the lateral hypothalamic peptide orexin in morphine dependence and withdrawal. The Journal of Neuroscience 2003, 23:3106-3111.
99. Gompf H.S., Aston-Jones G. Role of orexin input in the diurnal rhythm of locus coeruleus impulse activity. Brain Research 2008, 1224:43-52.
100. Gotter A.L., Roecker A.J., Hargreaves R., Coleman P.J., Winrow C.J., Renger J.J. Orexin receptors as therapeutic drug targets. Progress in Brain Research 2012, 198.
101. Gozzi A., Turrini G., Piccoli L., Massagrande M., Amantini D., Antolini M., et al. Functional magnetic resonance imaging reveals different neural substrates for the effects of orexin-1 and orexin-2 receptor antagonists. PLoS One 2011, 6:e16406.
102. Grabenhorst F., Rolls E.T. Value, pleasure and choice in the ventral prefrontal cortex. Trends in Cognitive Science 2011, 15:56-67.
103. Grace A.A., Floresco S.B., Goto Y., Lodge D.J. Regulation of firing of dopaminergic neurons and control of goal-directed behaviors. Trends in Neurosciences 2007, 30:220-227.
104. Griffond B., Risold P.Y., Jacquemard C., Colard C., Fellmann D. Insulin-induced hypoglycemia increases preprohypocretin (orexin) mRNA in the rat lateral hypothalamic area. Neuroscience Letters 1999, 262:77-80.
105. Grimm J.W., Hope B.T., Wise R.A., Shaham Y. Neuroadaptation. Incubation of cocaine craving after withdrawal. Nature 2001, 412:141-142.
106. Hakansson M., de Lecea L., Sutcliffe J.G., Yanagisawa M., Meister B. Leptin receptor- and STAT3-immunoreactivities in hypocretin/orexin neurones of the lateral hypothalamus. Journal of Neuroendocrinology 1999, 11:653-663.
107. Hamlin A.S., Clemens K.J., McNally G.P. Renewal of extinguished cocaine-seeking. Neuroscience 2008, 151:659-670.
108. Hamlin A.S., Newby J., McNally G.P. The neural correlates and role of D1 dopamine receptors in renewal of extinguished alcohol-seeking. Neuroscience 2007, 146:525-536.
109. Haney M., Ward A.S., Foltin R.W., Fischman M.W. Effects of ecopipam, a selective dopamine D1 antagonist, on smoked cocaine self-administration by humans. Psychopharmacology 2001, 155:330-337.
110. Harris G.C., Aston-Jones G. Altered motivation and learning following opiate withdrawal: Evidence for prolonged dysregulation of reward processing. Neuropsychopharmacology 2003, 28:865-871.
111. Harris G.C., Aston-Jones G. Arousal and reward: A dichotomy in orexin function. Trends in Neurosciences 2006, 29:571-577.
112. Harris G.C., Aston-Jones G. Activation in extended amygdala corresponds to altered hedonic processing during protracted morphine withdrawal. Behavioural Brain Research 2007, 176:251-258.
113. Harris G.C., Wimmer M., Aston-Jones G. A role for lateral hypothalamic orexin neurons in reward seeking. Nature 2005, 437:556-559.
114. Harris G.C., Wimmer M., Randall-Thompson J.F., Aston-Jones G. Lateral hypothalamic orexin neurons are critically involved in learning to associate an environment with morphine reward. Behavioural Brain Research 2007, 183:43-51.
115. Hata T., Chen J., Ebihara K., Date Y., Ishida Y., Nakahara D. Intra-ventral tegmental area or intracerebroventricular orexin-A increases the intra-cranial self-stimulation threshold via activation of the corticotropin-releasing factor system in rats. The European Journal of Neuroscience 2011, 34:816-826.
116. Haynes A.C., Jackson B., Chapman H., Tadayyon M., Johns A., Porter R.A., et al. A selective orexin-1 receptor antagonist reduces food consumption in male and female rats. Regulatory Peptides 2000, 96:45-51.
117. Haynes A.C., Jackson B., Overend P., Buckingham R.E., Wilson S., Tadayyon M., et al. Effects of single and chronic intracerebroventricular administration of the orexins on feeding in the rat. Peptides 1999, 20:1099-1105.
118. Heath R.G. Exploring the mind-brain relationship 1996, Moran Printing, Inc., Baton-Rouge, LA.
119. Hemby S.E., Co C., Koves T.R., Smith J.E., Dworkin S.I. Differences in extracellular dopamine concentrations in the nucleus accumbens during response-dependent and response-independent cocaine administration in the rat. Psychopharmacology 1997, 133:7-16.
120. Henny P., Jones B.E. Innervation of orexin/hypocretin neurons by GABAergic, glutamatergic or cholinergic basal forebrain terminals evidenced by immunostaining for presynaptic vesicular transporter and postsynaptic scaffolding proteins. The Journal of Comparative Neurology 2006, 499:645-661.
121. Hervieu G.J., Cluderay J.E., Harrison D.C., Roberts J.C., Leslie R.A. Gene expression and protein distribution of the orexin-1 receptor in the rat brain and spinal cord. Neuroscience 2001, 103:777-797.
122. Hinson R.E., Poulos C.X. Sensitization to the behavioral effects of cocaine: Modification by Pavlovian conditioning. Pharmacology, Biochemistry, and Behavior 1981, 15:559-562.
123. Hirose M., Egashira S., Goto Y., Hashihayata T., Ohtake N., Iwaasa H., et al. N-acyl 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline: The first orexin-2 receptor selective non-peptidic antagonist. Bioorganic & Medicinal Chemistry Letters 2003, 13:4497-4499.
124. Hollander J.A., Lu Q., Cameron M.D., Kamenecka T.M., Kenny P.J. Insular hypocretin transmission regulates nicotine reward. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:19480-19485.
125. Horvath T.L., Gao X.B. Input organization and plasticity of hypocretin neurons: Possible clues to obesity's association with insomnia. Cell Metabolism 2005, 1:279-286.
126. Huang H., Acuna-Goycolea C., Li Y., Cheng H.M., Obrietan K., van den Pol A.N. Cannabinoids excite hypothalamic melanin-concentrating hormone but inhibit hypocretin/orexin neurons: Implications for cannabinoid actions on food intake and cognitive arousal. The Journal of Neuroscience 2007, 27:4870-4881.
127. Hutcheson D.M., Quarta D., Halbout B., Rigal A., Valerio E., Heidbreder C. Orexin-1 receptor antagonist SB-334867 reduces the acquisition and expression of cocaine-conditioned reinforcement and the expression of amphetamine-conditioned reward. Behavioural Pharmacology 2011, 22:173-181.
128. Hyman S.E., Malenka R.C., Nestler E.J. Neural mechanisms of addiction: The role of reward-related learning and memory. Annual Review of Neuroscience 2006, 29:565-598.
129. Ikemoto S., Panksepp J. The role of nucleus accumbens dopamine in motivated behavior: A unifying interpretation with special reference to reward-seeking. Brain Research. Brain Research Reviews 1999, 31:6-41.
130. Ishii Y., Blundell J.E., Halford J.C., Upton N., Porter R., Johns A., et al. Anorexia and weight loss in male rats 24 h following single dose treatment with orexin-1 receptor antagonist SB-334867. Behavioural Brain Research 2005, 157:331-341.
131. Jacobs E.H., Smit A.B., de Vries T.J., Schoffelmeer A.N. Long-term gene expression in the nucleus accumbens following heroin administration is subregion-specific and depends on the nature of drug administration. Addiction Biology 2005, 10:91-100.
132. James M.H., Charnley J.L., Levi E.M., Jones E., Yeoh J.W., Smith D.W., et al. Orexin-1 receptor signalling within the ventral tegmental area, but not the paraventricular thalamus, is critical to regulating cue-induced reinstatement of cocaine-seeking. The International Journal of Neuropsychopharmacology 2011, 14:684-690.
133. Johnson P.L., Molosh A.I., Fitz S.D., Truitt W.A., Shekhar A. Orexin, stress and anxiety states. Progress in Brain Research 2012, 198.
134. Jupp B., Krivdic B., Krstew E., Lawrence A.J. The orexin(1) receptor antagonist SB-334867 dissociates the motivational properties of alcohol and sucrose in rats. Brain Research 2011, 1391:54-59.
135. Jupp B., Krstew E., Dezsi G., Lawrence A.J. Discrete cue-conditioned alcohol-seeking after protracted abstinence: Pattern of neural activation and involvement of orexin receptors. British Journal of Pharmacology 2011, 162:880-889.
136. Kalivas P.W., Stewart J. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Research. Brain Research Reviews 1991, 16:223-244.
137. Kalivas P.W., Volkow N., Seamans J. Unmanageable motivation in addiction: A pathology in prefrontal-accumbens glutamate transmission. Neuron 2005, 45:647-650.
138. Kallupi M., Cannella N., Economidou D., Ubaldi M., Ruggeri B., Weiss F., et al. Neuropeptide S facilitates cue-induced relapse to cocaine seeking through activation of the hypothalamic hypocretin system. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:19567-19572.
139. Kane J.K., Parker S.L., Li M.D. Hypothalamic orexin-A binding sites are downregulated by chronic nicotine treatment in the rat. Neuroscience Letters 2001, 298:1-4.
140. Kane J.K., Parker S.L., Matta S.G., Fu Y., Sharp B.M., Li M.D. Nicotine up-regulates expression of orexin and its receptors in rat brain. Endocrinology 2000, 141:3623-3629.
141. Karnani M.M., Apergis-Schoute J., Adamantidis A., Jensen L.T., de Lecea L., Fugger L., et al. Activation of central orexin/hypocretin neurons by dietary amino acids. Neuron 2011, 72:616-629.
142. Katz J.L., Higgins S.T. The validity of the reinstatement model of craving and relapse to drug use. Psychopharmacology 2003, 168:21-30.
143. Kelley A.E., Bakshi V.P., Haber S.N., Steininger T.L., Will M.J., Zhang M. Opioid modulation of taste hedonics within the ventral striatum. Physiology and Behavior 2002, 76:365-377.
144. Kelley A.E., Baldo B.A., Pratt W.E., Will M.J. Corticostriatal-hypothalamic circuitry and food motivation: Integration of energy, action and reward. Physiology and Behavior 2005, 86:773-795.
145. Kelley A.E., Berridge K.C. The neuroscience of natural rewards: Relevance to addictive drugs. The Journal of Neuroscience 2002, 22:3306-3311.
146. Kessler M., Arai A.C. Use of [3H]fluorowillardiine to study properties of AMPA receptor allosteric modulators. Brain Research 2006, 1076:25-41.
147. Koob G.F. Neural mechanisms of drug reinforcement. Annals of the New York Academy of Sciences 1992, 654:171-191.
148. Koob G.F., Le Moal M. Drug abuse: Hedonic homeostatic dysregulation. Science 1997, 278:52-58.
149. Koob G.F., Le Moal M. Neurobiology of addiction 2006, Academic Press, Amsterdam.
150. Korotkova T.M., Sergeeva O.A., Eriksson K.S., Haas H.L., Brown R.E. Excitation of ventral tegmental area dopaminergic and nondopaminergic neurons by orexins/hypocretins. The Journal of Neuroscience 2003, 23:7-11.
151. Kringelbach M.L., O'Doherty J., Rolls E.T., Andrews C. Activation of the human orbitofrontal cortex to a liquid food stimulus is correlated with its subjective pleasantness. Cerebral Cortex 2003, 13:1064-1071.
152. LaLumiere R.T., Niehoff K.E., Kalivas P.W. The infralimbic cortex regulates the consolidation of extinction after cocaine self-administration. Learning and Memory 2010, 17:168-175.
153. Langmead C.J., Jerman J.C., Brough S.J., Scott C., Porter R.A., Herdon H.J. Characterisation of the binding of [3H]-SB-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor. British Journal of Pharmacology 2004, 141:340-346.
154. Lawrence A.J. Regulation of alcohol-seeking by orexin (hypocretin) neurons. Brain Research 2010, 1314:124-129.
155. Lawrence A.J., Cowen M.S., Yang H.J., Chen F., Oldfield B. The orexin system regulates alcohol-seeking in rats. British Journal of Pharmacology 2006, 148:752-759.
156. Leri F., Flores J., Rodaros D., Stewart J. Blockade of stress-induced but not cocaine-induced reinstatement by infusion of noradrenergic antagonists into the bed nucleus of the stria terminalis or the central nucleus of the amygdala. The Journal of Neuroscience 2002, 22:5713-5718.
157. LeSage M.G., Perry J.L., Kotz C.M., Shelley D., Corrigall W.A. Nicotine self-administration in the rat: Effects of hypocretin antagonists and changes in hypocretin mRNA. Psychopharmacology 2010, 209:203-212.
158. Lesse H., Harper R.K. Frequency-related, bidirectional limbic responses to cocaine: Comparisons with amphetamine and lidocaine. Brain Research 1985, 335:21-31.
159. Leyton M. Conditioned and sensitized responses to stimulant drugs in humans. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2007, 31:1601-1613.
160. Li Y., van den Pol A.N. Direct and indirect inhibition by catecholamines of hypocretin/orexin neurons. The Journal of Neuroscience 2005, 25:173-183.
161. Li Y., van den Pol A.N. Differential target-dependent actions of coexpressed inhibitory dynorphin and excitatory hypocretin/orexin neuropeptides. The Journal of Neuroscience 2006, 26:13037-13047.
162. Li Y., van den Pol A.N. Mu-opioid receptor-mediated depression of the hypothalamic hypocretin/orexin arousal system. The Journal of Neuroscience 2008, 28:2814-2819.
163. Li Y., Wang H., Qi K., Chen X., Li S., Sui N., et al. Orexins in the midline thalamus are involved in the expression of conditioned place aversion to morphine withdrawal. Physiology and Behavior 2011, 102:42-50.
164. Lin L., Faraco J., Li R., Kadotani H., Rogers W., Lin X., et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999, 98:365-376.
165. Liu R.J., van den Pol A.N., Aghajanian G.K. Hypocretins (orexins) regulate serotonin neurons in the dorsal raphe nucleus by excitatory direct and inhibitory indirect actions. The Journal of Neuroscience 2002, 22:9453-9464.
166. Luo A.H., Tahsili-Fahadan P., Wise R.A., Lupica C.R., Aston-Jones G. Linking context with reward: A functional circuit from hippocampal CA3 to ventral tegmental area. Science 2011, 333:353-357.
167. Lutter M., Krishnan V., Russo S.J., Jung S., McClung C.A., Nestler E.J. Orexin signaling mediates the antidepressant-like effect of calorie restriction. The Journal of Neuroscience 2008, 28:3071-3075.
168. Mahler S.V., Smith R.J., Aston-Jones G. Interactions between VTA orexin and glutamate in cue-induced reinstatement of cocaine seeking in rats. Psychopharmacology 2012, (Berl). (PMID: 22411428). [epub ahead of print].
169. Malherbe P., Borroni E., Gobbi L., Knust H., Nettekoven M., Pinard E., et al. Biochemical and behavioural characterization of EMPA, a novel high-affinity, selective antagonist for the OX(2) receptor. British Journal of Pharmacology 2009, 156:1326-1341.
170. Marchant N.J., Hamlin A.S., McNally G.P. Lateral hypothalamus is required for context-induced reinstatement of extinguished reward seeking. The Journal of Neuroscience 2009, 29:1331-1342.
171. Marcus J.N., Aschkenasi C.J., Lee C.E., Chemelli R.M., Saper C.B., Yanagisawa M., et al. Differential expression of orexin receptors 1 and 2 in the rat brain. The Journal of Comparative Neurology 2001, 435:6-25.
172. Markou A., Weiss F., Gold L.H., Caine S.B., Schulteis G., Koob G.F. Animal models of drug craving. Psychopharmacology 1993, 112:163-182.
173. Martin-Fardon R., Zorrilla E.P., Ciccocioppo R., Weiss F. Role of innate and drug-induced dysregulation of brain stress and arousal systems in addiction: Focus on corticotropin-releasing factor, nociceptin/orphanin FQ, and orexin/hypocretin. Brain Research 2010, 1314:145-161.
174. McDonald P. Summary of the probe development effort to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1) [Summary]. Ed. S. R. I. M. S. Center. PubChem. 2011.
175. McGregor R., Wu M.F., Barber G., Ramanathan L., Siegel J.M. Highly specific role of hypocretin (orexin) neurons: Differential activation as a function of diurnal phase, operant reinforcement versus operant avoidance and light level. The Journal of Neuroscience 2011, 31:15455-15467.
176. McPherson C.S., Featherby T., Krstew E., Lawrence A.J. Quantification of phosphorylated cAMP-response element-binding protein expression throughout the brain of amphetamine-sensitized rats: Activation of hypothalamic orexin A-containing neurons. The Journal of Pharmacology and Experimental Therapeutics 2007, 323:805-812.
177. Meil W.M., See R.E. Conditioned cued recovery of responding following prolonged withdrawal from self-administered cocaine in rats: An animal model of relapse. Behavioural Pharmacology 1996, 7:754-763.
178. Mieda M., Sakurai T. Overview of orexin/hypocretin system. Progress in Brain Research 2012, 198.
179. Mignot E., Taheri S., Nishino S. Sleeping with the hypothalamus: Emerging therapeutic targets for sleep disorders. Nature Neuroscience 2002, 5(Suppl.):1071-1075.
180. Millan E.Z., Furlong T.M., McNally G.P. Accumbens shell-hypothalamus interactions mediate extinction of alcohol seeking. The Journal of Neuroscience 2010, 30:4626-4635.
181. Millan M.J., Newman-Tancredi A., Audinot V., Cussac D., Lejeune F., Nicolas J.P., et al. Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states. Synapse 2000, 35:79-95.
182. Miller E.K., Cohen J.D. An integrative theory of prefrontal cortex function. Annual Review of Neuroscience 2001, 24:167-202.
183. Milligan G., Smith N.J. Allosteric modulation of heterodimeric G-protein-coupled receptors. Trends in Pharmacological Sciences 2007, 28:615-620.
184. Moorman D.E., Aston-Jones G. Orexin-1 receptor antagonism decreases ethanol consumption and preference selectively in high-ethanol-preferring Sprague-Dawley rats. Alcohol 2009, 43:379-386.
185. Moorman D.E., Aston-Jones G. Orexin/hypocretin modulates response of ventral tegmental dopamine neurons to prefrontal activation: Diurnal influences. The Journal of Neuroscience 2010, 30:15585-15599.
186. Morganstern I., Chang G.Q., Barson J.R., Ye Z., Karatayev O., Leibowitz S.F. Differential effects of acute and chronic ethanol exposure on orexin expression in the perifornical lateral hypothalamus. Alcoholism, Clinical and Experimental Research 2010, 34:886-896.
187. Mori K., Kim J., Sasaki K. Electrophysiological effects of orexin-B and dopamine on rat nucleus accumbens shell neurons in vitro. Peptides 2011, 32:246-252.
188. Moriguchi T., Sakurai T., Nambu T., Yanagisawa M., Goto K. Neurons containing orexin in the lateral hypothalamic area of the adult rat brain are activated by insulin-induced acute hypoglycemia. Neuroscience Letters 1999, 264:101-104.
189. Mukai K., Kim J., Nakajima K., Oomura Y., Wayner M.J., Sasaki K. Electrophysiological effects of orexin/hypocretin on nucleus accumbens shell neurons in rats: An in vitro study. Peptides 2009, 30:1487-1496.
190. Muraki Y., Yamanaka A., Tsujino N., Kilduff T.S., Goto K., Sakurai T. Serotonergic regulation of the orexin/hypocretin neurons through the 5-HT1A receptor. The Journal of Neuroscience 2004, 24:7159-7166.
191. Murphy J.A., Deurveilher S., Semba K. Stimulant doses of caffeine induce c-FOS activation in orexin/hypocretin-containing neurons in rat. Neuroscience 2003, 121:269-275.
192. Muschamp J.W., Dominguez J.M., Sato S.M., Shen R.Y., Hull E.M. A role for hypocretin (orexin) in male sexual behavior. The Journal of Neuroscience 2007, 27:2837-2845.
193. Nair S.G., Adams-Deutsch T., Pickens C.L., Shaham Y. Role of dopamine receptors, but not a2 adrenoceptors, in yohimbine-induced reinstatement of high-fat food seeking 2009, Society for Neuroscience. Society for Neuroscience, San Diego, CA.
194. Nair S.G., Golden S.A., Shaham Y. Differential effects of the hypocretin 1 receptor antagonist SB 334867 on high-fat food self-administration and reinstatement of food seeking in rats. British Journal of Pharmacology 2008, 154:406-416.
195. Nambu T., Sakurai T., Mizukami K., Hosoya Y., Yanagisawa M., Goto K. Distribution of orexin neurons in the adult rat brain. Brain Research 1999, 827:243-260.
196. Naqvi N.H., Rudrauf D., Damasio H., Bechara A. Damage to the insula disrupts addiction to cigarette smoking. Science 2007, 315:531-534.
197. Narita M., Nagumo Y., Hashimoto S., Khotib J., Miyatake M., Sakurai T., et al. Direct involvement of orexinergic systems in the activation of the mesolimbic dopamine pathway and related behaviors induced by morphine. The Journal of Neuroscience 2006, 26:398-405.
198. Narita M., Nagumo Y., Miyatake M., Ikegami D., Kurahashi K., Suzuki T. Implication of protein kinase C in the orexin-induced elevation of extracellular dopamine levels and its rewarding effect. The European Journal of Neuroscience 2007, 25:1537-1545.
199. Nesse R.M., Berridge K.C. Psychoactive drug use in evolutionary perspective. Science 1997, 278:63-66.
200. NIDA (2009). Principals of Drug Addiction Treatment: A Research-Based Guide. Ed. D. o. H. a. H. S. National Institutes of Health. NIH. 2009.
201. Niimi M., Sato M., Taminato T. Neuropeptide Y in central control of feeding and interactions with orexin and leptin. Endocrine 2001, 14:269-273.
202. O'Brien C.P., Childress A.R., McLellan A.T., Ehrman R. Classical conditioning in drug-dependent humans. Annals of the New York Academy of Sciences 1992, 654:400-415.
203. O'Connor E.C., Chapman K., Butler P., Mead A.N. The predictive validity of the rat self-administration model for abuse liability. Neuroscience and Biobehavioral Reviews 2011, 35:912-938.
204. O'Doherty J.P., Deichmann R., Critchley H.D., Dolan R.J. Neural responses during anticipation of a primary taste reward. Neuron 2002, 33:815-826.
205. Ohno K., Hondo M., Sakurai T. Cholinergic regulation of orexin/hypocretin neurons through M(3) muscarinic receptor in mice. Journal of Pharmacological Sciences 2008, 106:485-491.
206. Olds J., Milner P. Positive reinforcement produced by electrical stimulation of septal area and other regions of rat brain. Journal of Comparative and Physiological Psychology 1954, 47:419-427.
207. Oleson E.B., Roberts D.C. Behavioral economic assessment of price and cocaine consumption following self-administration histories that produce escalation of either final ratios or intake. Neuropsychopharmacology 2009, 34:796-804.
208. Pandit R., de Jong J.W., Vanderschuren L.J., Adan R.A. Neurobiology of overeating and obesity: The role of melanocortins and beyond. European Journal of Pharmacology 2011, 660:28-42.
209. Panlilio L.V., Goldberg S.R. Self-administration of drugs in animals and humans as a model and an investigative tool. Addiction 2007, 102:1863-1870.
210. Pasumarthi R.K., Reznikov L.R., Fadel J. Activation of orexin neurons by acute nicotine. European Journal of Pharmacology 2006, 535:172-176.
211. Peters Y.M., O'Donnell P., Carelli R.M. Prefrontal cortical cell firing during maintenance, extinction, and reinstatement of goal-directed behavior for natural reward. Synapse 2005, 56:74-83.
212. Petrovich G.D., Reppucci C. Selective activation of the hypothalamic peptide orexin/hypocretin, but not melanin-concentrating hormone by a learned cue that stimulates feeding in sated rats 2011, Society for Neuroscience, 2011, Washington, DC, Program No. 285.23 2011 Neuroscience Meeting Planner. Online.
213. Peyron C., Tighe D.K., van den Pol A.N., de Lecea L., Heller H.C., Sutcliffe J.G., et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. The Journal of Neuroscience 1998, 18:9996-10015.
214. Phillips A.G., Vacca G., Ahn S. A top-down perspective on dopamine, motivation and memory. Pharmacology, Biochemistry, and Behavior 2008, 90:236-249.
215. Piazza P.V., Deminiere J.M., le Moal M., Simon H. Stress- and pharmacologically-induced behavioral sensitization increases vulnerability to acquisition of amphetamine self-administration. Brain Research 1990, 514:22-26.
216. Piazza P.V., Deminiere J.M., Maccari S., Mormede P., Le Moal M., Simon H. Individual reactivity to novelty predicts probability of amphetamine self-administration. Behavioural Pharmacology 1990, 1:339-345.
217. Pickens C.L., Airavaara M., Theberge F., Fanous S., Hope B.T., Shaham Y. Neurobiology of the incubation of drug craving. Trends in Neurosciences 2011, 34:411-420.
218. Pickens R., Thompson T. Characteristics of stimulant reinforcement. Stimulus properties of drugs 1971, Appleton-Century-Crofts, New York. T. Thompson, R. Pickens (Eds.).
219. Pierce R.C., Vanderschuren L.J. Kicking the habit: The neural basis of ingrained behaviors in cocaine addiction. Neuroscience and Biobehavioral Reviews 2010, 35:212-219.
220. Plaza-Zabala A., Flores A., Maldonado R., Berrendero F. Hypocretin/orexin signaling in the hypothalamic paraventricular nucleus is essential for the expression of nicotine withdrawal. Biological Psychiatry 2011, 71:214-223.
221. Plaza-Zabala A., Martin-Garcia E., de Lecea L., Maldonado R., Berrendero F. Hypocretins regulate the anxiogenic-like effects of nicotine and induce reinstatement of nicotine-seeking behavior. The Journal of Neuroscience 2010, 30:2300-2310.
222. Porter R.A., Chan W.N., Coulton S., Johns A., Hadley M.S., Widdowson K., et al. 1,3-Biarylureas as selective non-peptide antagonists of the orexin-1 receptor. Bioorganic & Medicinal Chemistry Letters 2001, 11:1907-1910.
223. Quarta D., Valerio E., Hutcheson D.M., Hedou G., Heidbreder C. The orexin-1 receptor antagonist SB-334867 reduces amphetamine-evoked dopamine outflow in the shell of the nucleus accumbens and decreases the expression of amphetamine sensitization. Neurochemistry International 2010, 56:11-15.
224. Ranaldi R., Kest K., Zellner M.R., Lubelski D., Muller J., Cruz Y., et al. The effects of VTA NMDA receptor antagonism on reward-related learning and associated c-fos expression in forebrain. Behavioural Brain Research 2011, 216:424-432.
225. Reissner K.J., Sartor G.C., Vazey E.M., Dunn T.E., Aston-Jones G., Kalivas P.W. Use of vivo-morpholinos for control of protein expression in the adult rat brain. Journal of Neuroscience Methods 2012, 203:354-360.
226. Richards J.K., Simms J.A., Steensland P., Taha S.A., Borgland S.L., Bonci A., et al. Inhibition of orexin-1/hypocretin-1 receptors inhibits yohimbine-induced reinstatement of ethanol and sucrose seeking in Long-Evans rats. Psychopharmacology 2008, 199:109-117.
227. Richardson K.A., Aston-Jones G. Lateral hypothalamic orexin/hypocretin neurons that project to VTA are differentially activated with morphine preference. The Journal of Neuroscience 2012, 32:3809-3817.
228. Richardson N.R., Roberts D.C. Progressive ratio schedules in drug self-administration studies in rats: a method to evaluate reinforcing efficacy. Journal of Neuroscience Methods 1996, 66(1):1-11.
229. Riday T.T., Fish E.W., Robinson J.E., Jarrett T.M., McGuigan M.M., Malanga C.J. Orexin-1 receptor antagonism does not reduce the rewarding potency of cocaine in Swiss-Webster mice. Brain Research 2011, 1431:53-61.
230. Risinger F.O., Dickinson S.D., Cunningham C.L. Haloperidol reduces ethanol-induced motor activity stimulation but not conditioned place preference. Psychopharmacology 1992, 107:453-456.
231. Risold P.Y., Swanson L.W. Chemoarchitecture of the rat lateral septal nucleus. Brain Research. Brain Research Reviews 1997, 24:91-113.
232. Risold P.Y., Swanson L.W. Connections of the rat lateral septal complex. Brain Research. Brain Research Reviews 1997, 24:115-195.
233. Robinson T.E., Becker J.B. Enduring changes in brain and behavior produced by chronic amphetamine administration: A review and evaluation of animal models of amphetamine psychosis. Brain Research 1986, 396:157-198.
234. Robinson T.E., Berridge K.C. The neural basis of drug craving: An incentive-sensitization theory of addiction. Brain Research. Brain Research Reviews 1993, 18:247-291.
235. Robinson T.E., Berridge K.C. Review. The incentive sensitization theory of addiction: Some current issues. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences 2008, 363:3137-3146.
236. Robinson T.E., Browman K.E., Crombag H.S., Badiani A. Modulation of the induction or expression of psychostimulant sensitization by the circumstances surrounding drug administration. Neuroscience and Biobehavioral Reviews 1998, 22:347-354.
237. Rodgers R.J., Halford J.C., Nunes de Souza R.L., Canto de Souza A.L., Piper D.C., Arch J.R., et al. SB-334867, a selective orexin-1 receptor antagonist, enhances behavioural satiety and blocks the hyperphagic effect of orexin-A in rats. The European Journal of Neuroscience 2001, 13:1444-1452.
238. Roecker A.J., Coleman P.J. Orexin receptor antagonists: Medicinal chemistry and therapeutic potential. Current Topics in Medicinal Chemistry 2008, 8:977-987.
239. Rogan S.C., Roth B.L. Remote control of neuronal signaling. Pharmacological Reviews 2011, 63:291-315.
240. Root D.H., Fabbricatore A.T., Barker D.J., Ma S., Pawlak A.P., West M.O. Evidence for habitual and goal-directed behavior following devaluation of cocaine: A multifaceted interpretation of relapse. PLoS One 2009, 4:e7170.
241. Sakurai T. Roles of orexins in the regulation of feeding and arousal. Sleep Medicine 2002, 3(Suppl. 2):S3-S9.
242. Sakurai T., Amemiya A., Ishii M., Matsuzaki I., Chemelli R.M., Tanaka H., et al. Orexins and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998, 92:573-585.
243. Sakurai T., Nagata R., Yamanaka A., Kawamura H., Tsujino N., Muraki Y., et al. Input of orexin/hypocretin neurons revealed by a genetically encoded tracer in mice. Neuron 2005, 46:297-308.
244. Salamone J.D., Correa M., Farrar A., Mingote S.M. Effort-related functions of nucleus accumbens dopamine and associated forebrain circuits. Psychopharmacology 2007, 191:461-482.
245. Sano H., Yokoi M. Striatal medium spiny neurons terminate in a distinct region in the lateral hypothalamic area and do not directly innervate orexin/hypocretin- or melanin-concentrating hormone-containing neurons. The Journal of Neuroscience 2007, 27:6948-6955.
246. Saper C.B., Chou T.C., Elmquist J.K. The need to feed: Homeostatic and hedonic control of eating. Neuron 2002, 36:199-211.
247. Sartor G.C., Aston-Jones G. A septal-hypothalamic pathway drives orexin neurons which is necessary for conditioned cocaine preference. The Journal of Neuroscience 2012, 32:4623-4631.
248. Satoh T., Nakai S., Sato T., Kimura M. Correlated coding of motivation and outcome of decision by dopamine neurons. The Journal of Neuroscience 2003, 23:9913-9923.
249. Scammell T.E., Winrow C.J. Orexin receptors: Pharmacology and therapeutic opportunities. Annual Review of Pharmacology and Toxicology 2011, 51:243-266.
250. Schindler C.W., Panlilio L.V., Goldberg S.R. Second-order schedules of drug self-administration in animals. Psychopharmacology 2002, 163:327-344.
251. Schneider E.R., Rada P., Darby R.D., Leibowitz S.F., Hoebel B.G. Orexigenic peptides and alcohol intake: Differential effects of orexin, galanin, and ghrelin. Alcoholism, Clinical and Experimental Research 2007, 31:1858-1865.
252. Schultz W. Behavioral dopamine signals. Trends in Neurosciences 2007, 30:203-210.
253. Scott M.M., Marcus J.N., Pettersen A., Birnbaum S.G., Mochizuki T., Scammell T.E., et al. Hcrtr1 and 2 signaling differentially regulates depression-like behaviors. Behavioural Brain Research 2011, 222:289-294.
254. See R.E., Waters R.P. Pharmacologically-induced stress: A cross-species probe for translational research in drug addiction and relapse. American Journal of Translational Research 2010, 3:81-89.
255. Segal D.S., Geyer M.A., Schuckit M.A. Stimulant-induced psychosis: An evaluation of animal methods. Essays in Neurochemistry and Neuropharmacology 1981, 5:95-129.
256. Sekiguchi M., Fleck M.W., Mayer M.L., Takeo J., Chiba Y., Yamashita S., et al. A novel allosteric potentiator of AMPA receptors: 4-2-(phenylsulfonylamino)ethylthio-2,6-difluoro-phenoxyacetamide. The Journal of Neuroscience 1997, 17:5760-5771.
257. Shaham Y., Erb S., Stewart J. Stress-induced relapse to heroin and cocaine seeking in rats: A review. Brain Research. Brain Research Reviews 2000, 33:13-33.
258. Shaham Y., Shalev U., Lu L., De Wit H., Stewart J. The reinstatement model of drug relapse: History, methodology and major findings. Psychopharmacology 2003, 168:3-20.
259. Shalev U., Erb S., Shaham Y. Role of CRF and other neuropeptides in stress-induced reinstatement of drug seeking. Brain Research 2010, 1314:15-28.
260. Sharf R., Guarnieri D.J., Taylor J.R., DiLeone R.J. Orexin mediates morphine place preference, but not morphine-induced hyperactivity or sensitization. Brain Research 2010, 1317:24-32.
261. Sharf R., Sarhan M., Brayton C.E., Guarnieri D.J., Taylor J.R., DiLeone R.J. Orexin signaling via the orexin 1 receptor mediates operant responding for food reinforcement. Biological Psychiatry 2010, 67:753-760.
262. Sharf R., Sarhan M., Dileone R.J. Orexin mediates the expression of precipitated morphine withdrawal and concurrent activation of the nucleus accumbens shell. Biological Psychiatry 2008, 64:175-183.
263. Shoblock J.R., Welty N., Aluisio L., Fraser I., Motley S.T., Morton K., et al. Selective blockade of the orexin-2 receptor attenuates ethanol self-administration, place preference, and reinstatement. Psychopharmacology 2011, 215:191-203.
264. Shoji S., Simms D., Yamada K., Gallagher J.P. Cocaine administered in vitro to brain slices from rats treated with cocaine chronically in vivo results in a gamma-aminobutyric acid receptor-mediated hyperpolarization recorded from the dorsolateral septum. The Journal of Pharmacology and Experimental Therapeutics 1998, 286:509-518.
265. Siegel J.M. Hypocretin (orexin): Role in normal behavior and neuropathology. Annual Review of Psychology 2004, 55:125-148.
266. Simms D., Gallagher J.P. Modification of serotonin responses in rat dorsolateral septal nucleus neurons by acute and chronic cocaine. The Journal of Pharmacology and Experimental Therapeutics 1996, 276:1292-1303.
267. Simms J.A., Steensland P., Medina B., Abernathy K.E., Chandler L.J., Wise R., et al. Intermittent access to 20% ethanol induces high ethanol consumption in Long-Evans and Wistar rats. Alcoholism, Clinical and Experimental Research 2008, 32:1816-1823.
268. Sinha R., Fox H.C., Hong K.I., Hansen J., Tuit K., Kreek M.J. Effects of adrenal sensitivity, stress- and cue-induced craving, and anxiety on subsequent alcohol relapse and treatment outcomes. Archives of General Psychiatry 2011, 68:942-952.
269. Sinha R., Li C.S. Imaging stress- and cue-induced drug and alcohol craving: Association with relapse and clinical implications. Drug and Alcohol Review 2007, 26:25-31.
270. Smart D., Sabido-David C., Brough S.J., Jewitt F., Johns A., Porter R.A., et al. SB-334867-A: The first selective orexin-1 receptor antagonist. British Journal of Pharmacology 2001, 132:1179-1182.
271. Smith R.J., Aston-Jones G. alpha(2) Adrenergic and imidazoline receptor agonists prevent cue-induced cocaine seeking. Biological Psychiatry 2011, 70:712-719.
272. Smith R.J., Aston-Jones G. Orexin/hypocretin 1 receptor antagonist reduces heroin self-administration and cue-induced heroin seeking. The European Journal of Neuroscience 2012, 35:798-804.
273. Smith K.S., Berridge K.C. The ventral pallidum and hedonic reward: Neurochemical maps of sucrose " liking" and food intake. The Journal of Neuroscience 2005, 25:8637-8649.
274. Smith K.S., Mahler S.V., Pecina S., Berridge K.C. Hedonic hotspots: Generating sensory pleasure in the brain. Pleasures of the brain 2009, 27-49. Oxford University Press, Oxford, UK. M.L. Kringelback, K.C. Berridge (Eds.).
275. Smith R.J., See R.E., Aston-Jones G. Orexin/hypocretin signaling at the orexin 1 receptor regulates cue-elicited cocaine-seeking. The European Journal of Neuroscience 2009, 30:493-503.
276. Smith R.J., Tahsili-Fahadan P., Aston-Jones G. Orexin/hypocretin is necessary for context-driven cocaine-seeking. Neuropharmacology 2010, 58:179-184.
277. Smith K.S., Tindell A.J., Aldridge J.W., Berridge K.C. Ventral pallidum roles in reward and motivation. Behavioural Brain Research 2009, 196:155-167.
278. Steketee J.D., Kalivas P.W. Drug wanting: Behavioral sensitization and relapse to drug-seeking behavior. Pharmacological Reviews 2011, 63:348-365.
279. Stewart J., de Wit H., Eikelboom R. Role of unconditioned and conditioned drug effects in the self-administration of opiates and stimulants. Psychological Review 1984, 91:251-268.
280. Stewart J., Vezina P. Extinction procedures abolish conditioned stimulus control but spare sensitized responding to amphetamine. Behavioural Pharmacology 1991, 2:65-71.
281. Stratford T.R., Kelley A.E. GABA in the nucleus accumbens shell participates in the central regulation of feeding behavior. The Journal of Neuroscience 1997, 17:4434-4440.
282. Sutcliffe J.G., de Lecea L. The hypocretins: Excitatory neuromodulatory peptides for multiple homeostatic systems, including sleep and feeding. Journal of Neuroscience Research 2000, 62:161-168.
283. Suto N., Ecke L.E., You Z.B., Wise R.A. Extracellular fluctuations of dopamine and glutamate in the nucleus accumbens core and shell associated with lever-pressing during cocaine self-administration, extinction, and yoked cocaine administration. Psychopharmacology 2010, 211:267-275.
284. Suzuki R., Shimojima H., Funahashi H., Nakajo S., Yamada S., Guan J.L., et al. Orexin-1 receptor immunoreactivity in chemically identified target neurons in the rat hypothalamus. Neuroscience Letters 2002, 324:5-8.
285. Taslimi Z., Haghparast A., Hassanpour-Ezatti M., Safari M.S. Chemical stimulation of the lateral hypothalamus induces conditioned place preference in rats: Involvement of OX1 and CB1 receptors in the ventral tegmental area. Behavioural Brain Research 2011, 217:41-46.
286. Thannickal T.C., Moore R.Y., Nienhuis R., Ramanathan L., Gulyani S., Aldrich M., et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000, 27:469-474.
287. Thorpe A.J., Kotz C.M. Orexin A in the nucleus accumbens stimulates feeding and locomotor activity. Brain Research 2005, 1050:156-162.
288. Tong Z.Y., Overton P.G., Clark D. Stimulation of the prefrontal cortex in the rat induces patterns of activity in midbrain dopaminergic neurons which resemble natural burst events. Synapse 1996, 22:195-208.
289. Trivedi P., Yu H., MacNeil D.J., Van der Ploeg L.H., Guan X.M. Distribution of orexin receptor mRNA in the rat brain. FEBS Letters 1998, 438:71-75.
290. Tsujino N., Yamanaka A., Ichiki K., Muraki Y., Kilduff T.S., Yagami K., et al. Cholecystokinin activates orexin/hypocretin neurons through the cholecystokinin A receptor. The Journal of Neuroscience 2005, 25:7459-7469.
291. van den Pol A.N. Hypothalamic hypocretin (orexin): Robust innervation of the spinal cord. The Journal of Neuroscience 1999, 19:3171-3182.
292. Vanderschuren L.J., Everitt B.J. Drug seeking becomes compulsive after prolonged cocaine self-administration. Science 2004, 305:1017-1019.
293. Vezina P. Sensitization of midbrain dopamine neuron reactivity and the self-administration of psychomotor stimulant drugs. Neuroscience and Biobehavioral Reviews 2004, 27:827-839.
294. Vezina P., Stewart J. The effect of dopamine receptor blockade on the development of sensitization to the locomotor activating effects of amphetamine and morphine. Brain Research 1989, 499:108-120.
295. Vittoz N.M., Berridge C.W. Hypocretin/orexin selectively increases dopamine efflux within the prefrontal cortex: Involvement of the ventral tegmental area. Neuropsychopharmacology 2006, 31:384-395.
296. Vittoz N.M., Schmeichel B., Berridge C.W. Hypocretin/orexin preferentially activates caudomedial ventral tegmental area dopamine neurons. The European Journal of Neuroscience 2008, 28:1629-1640.
297. Volkow N.D., Wise R.A. How can drug addiction help us understand obesity?. Nature Neuroscience 2005, 8:555-560.
298. von der Goltz C., Koopmann A., Dinter C., Richter A., Grosshans M., Fink T., et al. Involvement of orexin in the regulation of stress, depression and reward in alcohol dependence. Hormones and Behavior 2011, 60:644-650.
299. von der Goltz C., Koopmann A., Dinter C., Richter A., Rockenbach C., Grosshans M., et al. Orexin and leptin are associated with nicotine craving: A link between smoking, appetite and reward. Psychoneuroendocrinology 2010, 35:570-577.
300. Voorhees C.M., Cunningham C.L. Involvement of the orexin/hypocretin system in ethanol conditioned place preference. Psychopharmacology 2011, 214:805-818.
301. Vorel S.R., Liu X., Hayes R.J., Spector J.A., Gardner E.L. Relapse to cocaine-seeking after hippocampal theta burst stimulation. Science 2001, 292:1175-1178.
302. Wanat M.J., Willuhn I., Clark J.J., Phillips P.E. Phasic dopamine release in appetitive behaviors and drug addiction. Current Drug Abuse Reviews 2009, 2:195-213.
303. Wang Z., Faith M., Patterson F., Tang K., Kerrin K., Wileyto E.P., et al. Neural substrates of abstinence-induced cigarette cravings in chronic smokers. The Journal of Neuroscience 2007, 27:14035-14040.
304. Wang B., You Z.B., Wise R.A. Reinstatement of cocaine seeking by hypocretin (orexin) in the ventral tegmental area: Independence from the local corticotropin-releasing factor network. Biological Psychiatry 2009, 65:857-862.
305. Wee S., Koob G.F. The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse. Psychopharmacology 2010, 210:121-135.
306. Welch C.C., Kim E.M., Grace M.K., Billington C.J., Levine A.S. Palatability-induced hyperphagia increases hypothalamic dynorphin peptide and mRNA levels. Brain Research 1996, 721:126-131.
307. Whitman D.B., Cox C.D., Breslin M.J., Brashear K.M., Schreier J.D., Bogusky M.J., et al. Discovery of a potent, CNS-penetrant orexin receptor antagonist based on an n, n-disubstituted-1,4-diazepane scaffold that promotes sleep in rats. ChemMedChem 2009, 4:1069-1074.
308. Willie J.T., Chemelli R.M., Sinton C.M., Tokita S., Williams S.C., Kisanuki Y.Y., et al. Distinct narcolepsy syndromes in orexin receptor-2 and orexin null mice: Molecular genetic dissection of non-REM and REM sleep regulatory processes. Neuron 2003, 38:715-730.
309. Winocur G., Gilbert M. The hippocampus, context, and information processing. Behavioral and Neural Biology 1984, 40:27-43.
310. Winrow C.J., Tanis K.Q., Reiss D.R., Rigby A.M., Uslaner J.M., Uebele V.N., et al. Orexin receptor antagonism prevents transcriptional and behavioral plasticity resulting from stimulant exposure. Neuropharmacology 2010, 58:185-194.
311. Winsky-Sommerer R., Boutrel B., de Lecea L. Stress and arousal: The corticotrophin-releasing factor/hypocretin circuitry. Molecular Neurobiology 2005, 32:285-294.
312. Wise R.A. Intravenous drug self-administration: A special case of positive reinforcement. Methods of assessing the reinforcing properties of abused drugs 1987, 117-141. Springer-Verlag, New York. M.A. Bozarth (Ed.).
313. Wise R.A. Addictive drugs and brain stimulation reward. Annual Review of Neuroscience 1996, 19:319-340.
314. Wise R.A. Drug self-administration viewed as ingestive behaviour. Appetite 1997, 28:1-5.
315. Wise R.A., Morales M. A ventral tegmental CRF-glutamate-dopamine interaction in addiction. Brain Research 2010, 1314:38-43.
316. Yamanaka A., Beuckmann C.T., Willie J.T., Hara J., Tsujino N., Mieda M., et al. Hypothalamic orexin neurons regulate arousal according to energy balance in mice. Neuron 2003, 38:701-713.
317. Yamanaka A., Muraki Y., Tsujino N., Goto K., Sakurai T. Regulation of orexin neurons by the monoaminergic and cholinergic systems. Biochemical and Biophysical Research Communications 2003, 303:120-129.
318. Yamanaka A., Sakurai T., Katsumoto T., Yanagisawa M., Goto K. Chronic intracerebroventricular administration of orexin-A to rats increases food intake in daytime, but has no effect on body weight. Brain Research 1999, 849:248-252.
319. Yeomans J.S. Principles of brain stimulation 1990, Oxford University Press, New York.
320. Yoshida Y., Fujiki N., Nakajima T., Ripley B., Matsumura H., Yoneda H., et al. Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep-wake activities. The European Journal of Neuroscience 2001, 14:1075-1081.
321. Yoshida K., McCormack S., Espana R.A., Crocker A., Scammell T.E. Afferents to the orexin neurons of the rat brain. The Journal of Comparative Neurology 2006, 494:845-861.
322. Yun I.A., Fields H.L. Basolateral amygdala lesions impair both cue- and cocaine-induced reinstatement in animals trained on a discriminative stimulus task. Neuroscience 2003, 121:747-757.
323. Zavala A.R., Weber S.M., Rice H.J., Alleweireldt A.T., Neisewander J.L. Role of the prelimbic subregion of the medial prefrontal cortex in acquisition, extinction, and reinstatement of cocaine-conditioned place preference. Brain Research 2003, 990:157-164.
324. Zellner M.R., Kest K., Ranaldi R. NMDA receptor antagonism in the ventral tegmental area impairs acquisition of reward-related learning. Behavioural Brain Research 2009, 197:442-449.
325. Zellner M.R., Ranaldi R. How conditioned stimuli acquire the ability to activate VTA dopamine cells: A proposed neurobiological component of reward-related learning. Neuroscience and Biobehavioral Reviews 2010, 34:769-780.
326. Zhang M., Balmadrid C., Kelley A.E. Nucleus accumbens opioid, GABaergic, and dopaminergic modulation of palatable food motivation: Contrasting effects revealed by a progressive ratio study in the rat. Behavioral Neuroscience 2003, 117:202-211.
327. Zhang G.C., Mao L.M., Liu X.Y., Wang J.Q. Long-lasting up-regulation of orexin receptor type 2 protein levels in the rat nucleus accumbens after chronic cocaine administration. Journal of Neurochemistry 2007, 103:400-407.
328. Zheng H., Patterson L.M., Berthoud H.R. Orexin signaling in the ventral tegmental area is required for high-fat appetite induced by opioid stimulation of the nucleus accumbens. The Journal of Neuroscience 2007, 27:11075-11082.
329. Zhou Y., Bendor J., Hofmann L., Randesi M., Ho A., Kreek M.J. Mu opioid receptor and orexin/hypocretin mRNA levels in the lateral hypothalamus and striatum are enhanced by morphine withdrawal. The Journal of Endocrinology 2006, 191:137-145.
330. Zhou Y., Cui C.L., Schlussman S.D., Choi J.C., Ho A., Han J.S., et al. Effects of cocaine place conditioning, chronic escalating-dose " binge" pattern cocaine administration and acute withdrawal on orexin/hypocretin and preprodynorphin gene expressions in lateral hypothalamus of Fischer and Sprague-Dawley rats. Neuroscience 2008, 153:1225-1234.
331. Zhou L., Ghee S.M., Chan C., Lin L., Cameron M.D., Kenny P.J., et al. Orexin-1 receptor mediation of cocaine-seeking in male and female rats. The Journal of Pharmacology and Experimental Therapeutics 2012, 340(3):801-809.
332. Zushida K., Sakurai M., Wada K., Sekiguchi M. Facilitation of extinction learning for contextual fear memory by PEPA: A potentiator of AMPA receptors. The Journal of Neuroscience 2007, 27:158-166.